News tagged with 'Reclast'

While a new study reassures patients who take bone-building drugs to treat osteoporosis, a recent study indicates that the quality of bone among users may be brittle. The latest study is sponsored by drug makers, Merck and Novartis.

The FDA responds to Fosamax studies warning of brittle bones with prolonged use.

Popular bone-building medications known as bisphosphonates may have a rare, but serious, cardiac side effect. A review of available research found these medications may increase the risk of atrial fibrillation -- a disorder that affects as many as 2.2 million Americans.

Bisphosphonates, are a class of drug used to treat osteoporosis that slows or stops the reabsorption of bone, which are being linked to a condition in which jawbone tissue dies.